## **REMARKS**

The claims have been amended to focus on screening methods for agents that decrease the function or production of 101P3A11 protein. Claims 31-38 have been replaced by claims 48-49. New claim 50 is supported by claim 31 as originally proposed. No new matter has been added and entry of the amendment is respectfully requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket No. <u>511582002420</u>.

Respectfully submitted,

Dated:

August 16, 2002

Rv

Kate H. Murashige

Registration No. 29,959

Morrison & Foerster LLP 3811 Valley Centre Drive

Suite 500

San Diego, California 92130-2332

Telephone: (858) 720-5112 Facsimile: (858) 720-5125

4